Quris-AI has built a platform that can simulate genetically diverse clinical trials on a chip. The technology may reduce biopharma’s need for animal testing and de-risk human testing.
Israeli-American biotech Quris-AI’s platform can test thousands of drug candidates on hundreds of miniaturized and genetically diverse collections of organs-on-a-chip, effectively creating a “clinical-trial-on-a-chip.” The robust AI-based approach predicts drug toxicity with a level of accuracy that won it a partnership with Merck KGaA.
“This method surpasses the limitations of traditional animal testing by leveraging vast amounts of unique, real-time data to refine machine...
A discussion with Karen Harris, CFO of the Alzheimer's Drug Discovery Foundation, about the foundation's investment strategy, biotech and investor sentiment at the recent BIO conference and what innovations give her hope for Alzheimer's patients.
Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.
While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.
